FDA Adverse Event Malfunction Summary report: N

CW HIGH RES SSP UNITRAYS KIT WITH TAQ

MDR report key: 2432862 · Received January 11, 2012

Report

Report Number
2244574-2012-00001
Event Type
Malfunction
Date Received
January 11, 2012
Date of Event
October 3, 2011
Report Date
January 10, 2012
Manufacturer
LIFE TECHNOLOGIES CORPORATION
Product Code
MZI
PMA / PMN Number
BK020068
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
AR, US
Reporter Occupation
NOT APPLICABLE

Narratives

Description of Event or Problem · 1

USING A SURVEY SAMPLE, THE CUSTOMER REPORTED THAT THERE WAS A FALSE POSITIVE BAND SEEN IN LANE 89 FOR A CONFIRMED SAMPLE TYPE OF HLA C 02:14. LANE 89 WAS LISTED ON THE KIT WORKSHEET/INTERPRETATION DOCUMENTATION (WHICH IS INCLUDED WITH EACH KIT) AS THE FOLLOWING: C 02:10^, HOWEVER THE DOCUMENTATION ALSO INDICATED THAT "ALLELES WRITTEN WITH THE "^" SYMBOL FOLLOWING THEM HAVE UNK SEQUENCES AT THE SENSE AND/OR ANTISENSE PRIMER ANNEALING SITE. THEIR REACTION PATTERNS ARE PREDICTED BASED ON SEQUENCE HEMOLOGY WITH EACH MAJOR HLA GROUP. INTERNAL INVESTIGATION CONFIRMED BY SEQUENCE BASED TYPING THAT THE CUSTOMER HAD A C 02:14 ALLELE. THEREFORE LANE 89 HAS A CONFIRMED FALSE POSITIVE IN THE AFFECTED KITS. THE C 02:14 ALLELE HAS AN UNK SEQUENCE REGION WHICH HAD NOT BEEN CONFIRMED THROUGH TESTING. IT IS NOW KNOWN THAT THE C 02:14 ALLELE HAS THE SAME POLYMORPHISM AS C 02:10 AND THE WORKSHEET IS INCORRECT IN LISTING THIS ALLELE AS NEGATIVE FOR LANE 89. WHEN AN ALLELE, SUCH AS THE C 02:14 ALLELE, CONTAINS A REGION WITH UNK DNA SEQUENCE, IT IS ASSIGNED ACCORDING TO THE COMMON ALLELES IN THAT MOLECULAR HLA GROUP. NO C02:14 SAMPLE WAS AVAILABLE FOR TESTING PRIOR TO THE COMPLAINT; THE LABELING STATED THE PRIMERS IN LANE 89 WOULD NOT AMPLIFY THIS SEQUENCE IN THE C 02:14 ALLELE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 CW HIGH RES SSP UNITRAYS KIT WITH TAQ MZI TEST, QUALITATIVE, FOR HLA, NON-DIAGNOSTIC MZI LIFE TECHNOLOGIES CORPORATION 005 928442

Patients

Seq Age Sex Outcome Treatment
1